NCT06765317 - A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 16, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)High Grade B Cell Lymphoma

Interventions

DRUG

Glofitamab

C1D8 2.5 mg iv; C1D15 10 mg iv; C2D1-onwards: 30 mg iv, every 3 weeks

DRUG

Polatuzumab

1.8 mg/kg iv C1D1 onwards, every 3 weeks

DRUG

Rituximab

375 mg/m2 iv D1

DRUG

Cyclophosphamide

400 mg/m2 iv D1

DRUG

Doxorubicin

25 mg/m2 iv D1

DRUG

Obinutuzumab:

1000 mg iv C1D1 (7 days prior to glofitamab administration) single dose

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale